PFIZER Inc said it will apply to U.S. health regulators on Friday for emergency use authorization (EUA) of its COVID-19 vaccine, the first such application in a major step toward providing protection against the new coronavirus.
The application to the U.S. Food and Drug Administration (FDA) comes just days after Pfizer and German partner BioNTech SE reported final trial results that showed the vaccine was 95% effective in preventing COVID-19 with no major safety concerns.
Pfizer's shares rose 2% and BioNTech climbed 5% on the news that a vaccine could soon be available, raising hopes for the end of a pandemic that has claimed more than a quarter of a million lives in the United States and over 1.3 million worldwide.
The application also includes safety data on about 100 children 12-15 years of age. The company said 45% of U.S. trial participants are 56-85 years old.
"Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine," Pfizer Chief Executive Officer Albert Bourla said in a statement.
The companies expect the FDA to grant the EUA by mid-December and said they will begin shipping doses almost immediately. Pfizer has said it expects to have 50 million vaccine doses ready this year, enough to protect 25 million people.
An FDA advisory committee tentatively plans to meet Dec. 8-10 to discuss the vaccine, a source familiar with the situation told Reuters, though the dates could change.
The final trial data showed the vaccine provided a similar level of protection across different ages and ethnicities - an encouraging result as the disease disproportionately hurts the elderly and minorities.
Of the 170 volunteers who contracted COVID-19 in Pfizer's trial involving over 43,000 people, 162 had received only a placebo, meaning the vaccine was 95% effective, far higher than originally expected. U.S. FDA had set minimum bar for efficacy of 50%.
Pfizer said nearly 42% of global participants and 30% of U.S. participants in the Phase 3 study have racially and ethnically diverse backgrounds.
Moderna Inc is expected to be the next company to seek a U.S. emergency use nod for a COVID-19 vaccine. An initial analysis of data from its late-stage trial showed the vaccine was 94.5% effective. Final results and safety data are expected in the coming days or weeks.
Both the Pfizer/BioNTech and Moderna vaccines work using a new technology to trigger an immune response known as synthetic messenger RNA that can be produced at scale much more quickly than traditional vaccines.
Of dozens of drugmakers and research institutions racing to develop COVID-19 vaccines, the next late-stage data is expected to come from AstraZeneca Plc, which is working with the University of Oxford, in November or December.
Johnson & Johnson said it expects to have data needed to seek U.S. authorization for its experimental vaccine by February.
Reuters
Fri Nov 20 2020
![Pfizer to submit U.S. emergency use application for COVID-19 vaccine Pfizer to submit U.S. emergency use application for COVID-19 vaccine](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2020-11/61605754485_Pfizer.jpg)
Syringes are seen in front of displayed Biontech and Pfizer logos in this illustration taken November 10, 2020. - Filepic/REUTERS
![Lebih 1,600 premis PKS sertai program SOLVE 4 SME Lebih 1,600 premis PKS sertai program SOLVE 4 SME](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-08/71723651455_TBSOLVE.jpg)
Lebih 1,600 premis PKS sertai program "SOLVE 4 SME"
JKKP memaklumkan penyertaan itu melebihi sasaran jabatan itu dan telah memberi manfaat kepada 70,824 pekerja PKS.
![PRK Nenggiri: PN ada peluang menang, tapi jangan over-confident - Muhyiddin PRK Nenggiri: PN ada peluang menang, tapi jangan over-confident - Muhyiddin](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-04/51713678198_MuhyiddinYassin.jpg)
PRK Nenggiri: "PN ada peluang menang, tapi jangan over-confident" - Muhyiddin
Muhyiddin optimis dengan kemenangan calon PN, Mohd Rizwadi Ismail sekali gus mempertahankan kerusi DUN Nenggiri.
![Ahli ekonomi yakin pertumbuhan KDNK sekitar 5.8 peratus pada suku kedua 2024 Ahli ekonomi yakin pertumbuhan KDNK sekitar 5.8 peratus pada suku kedua 2024](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-06/81717305735_EkonomiMalaysia.jpg)
Ahli ekonomi yakin pertumbuhan KDNK sekitar 5.8 peratus pada suku kedua 2024
Kalangan ahli ekonomi yakin KDNK Malaysia bagi suku kedua 2024 akan berkembang pada 5.8 peratus berbanding 4.2 peratus pada suku pertama tahun ini.
AWANI Pagi: Berita tumpuan & menarik di astroawani.com [15 Ogos 2024]
Antara fokus AWANI Pagi bersama Nursyazwani Saiful Sham dan Afiezy Azaman
- Mayat lelaki di jambatan Klang dipercayai YouTuber Nidza Afham
- BNM denda Maybank, CIMB kerana gangguan perkhidmatan berpanjangan
- JIWA SME: Inovasi kuih sejuk beku jadi kudapan jemaah tunai umrah
#AWANInews #AWANIpagi
- Mayat lelaki di jambatan Klang dipercayai YouTuber Nidza Afham
- BNM denda Maybank, CIMB kerana gangguan perkhidmatan berpanjangan
- JIWA SME: Inovasi kuih sejuk beku jadi kudapan jemaah tunai umrah
#AWANInews #AWANIpagi
![Cisco akan kurangkan 7 peratus tenaga kerja globalnya Cisco akan kurangkan 7 peratus tenaga kerja globalnya](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-08/41723681507_Ciscologo.jpg)
Cisco akan kurangkan 7 peratus tenaga kerja globalnya
Langkah mengurangkan kakitangan itu dijangka melibatkan kos pra-cukai sehingga AS$1 bilion.
Jiwa SME: Kuih tradisonal sejuk beku 'diterbangkan' ke Tanah Suci
Inovasi pembuatan makanan sejuk beku, terutama kuih muih tradisional telah berjaya membawa produk itu ke peringkat global, terutama dalam memenuhi citarasa jemaah haji dan umrah rakyat Malaysia di Tanah Suci Mekah dan Madinah.
![Gol sulung Mbappe bantu Real Madrid juarai Piala Super UEFA Gol sulung Mbappe bantu Real Madrid juarai Piala Super UEFA](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-08/51723679998_KylianMbappe.jpg)
Gol sulung Mbappe bantu Real Madrid juarai Piala Super UEFA
"Ia adalah malam yang hebat. Ia adalah detik yang hebat untuk saya. Dan kami memenangi kejuaraan, yang penting - di Madrid anda perlu sentiasa menang."
![“I love you Am, bahagialah di syurga firdausi” - Aufahanie “I love you Am, bahagialah di syurga firdausi” - Aufahanie](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2024-08/51723679258_AufahanieNidzaAfh.jpg)
“I love you Am, bahagialah di syurga firdausi” - Aufahanie
Air mata Aufahanie sudah kering meratapi pemergian abang tercinta, Nidza Afham yang ditemui meninggal dunia selepas dilaporkan hilang.
Konsert jelajah: Taylor Swift teruskan konsert London selepas ancaman keganasan
Taylor Swift akan meneruskan persembahan di London pada Khamis, meneruskan jelajah konsert terbesar dunia di tengah-tengah kebimbangan keselamatan susulan cubaan serangan Daesh memaksa pembatalan tarikh konsert di Vienna, minggu lalu.
Taliban rai ulang tahun ketiga pemerintahan Afghanistan
Kerajaan Taliban semalam meraikan ulang tahun ketiga pemerintahannya di Afghanistan dengan perarakan tentera yang memberi penghormatan kepada bom buatan sendiri yang digunakan ketika peperangan, pesawat pejuang dan perbarisan pasukan keselamatan.
![COVID-19: Vaksin mungkin peroleh lesen dalam beberapa minggu - Kementerian Kesihatan India COVID-19: Vaksin mungkin peroleh lesen dalam beberapa minggu - Kementerian Kesihatan India](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2020-12/61607327760_TBVaccineCovid.jpg)
COVID-19: Vaksin mungkin peroleh lesen dalam beberapa minggu - Kementerian Kesihatan India
Pegawai kesihatan berkata syarikat pengeluar vaksin Serum Institute of India sudah memohon kelulusan bagi penggunaan kecemasan di India.
![COVID-19: KKM masih menunggu dokumen Pfizer berhubung status vaksin COVID-19: KKM masih menunggu dokumen Pfizer berhubung status vaksin](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2020-11/81606622929_CovidVaksin.jpg)
COVID-19: KKM masih menunggu dokumen Pfizer berhubung status vaksin
KKM masih belum terima sebarang dokumen daripada Pfizer berhubung status terkini vaksin COVID-19
![Pfizer dan BioNtech kemuka permohonan kelulusan kecemasan penggunaan vaksin di AS, Eropah Pfizer dan BioNtech kemuka permohonan kelulusan kecemasan penggunaan vaksin di AS, Eropah](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2020-12/51606825247_TBCOVIDVACCINE.jpg)
Pfizer dan BioNtech kemuka permohonan kelulusan kecemasan penggunaan vaksin di AS, Eropah
Permohonan rasmi yang dikemukakan kedua-dua syarikat itu kepada Agensi Perubatan Eropah (EMA) dibuat sehari selepas permohonan sama dikemukaan di AS dan Britain.
![COVID-19: Australia pula umum vaksin selamat dan berkesan COVID-19: Australia pula umum vaksin selamat dan berkesan](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2020-11/71605235285_Vaccine.jpg)
COVID-19: Australia pula umum vaksin selamat dan berkesan
Vaksin itu membuktikan ia selamat melalui ujian klinikal fasa satu dan terbukti menghasilkan tindak balas antibodi positif.